NCT07241533Recruiting
Asiaticoside for Treating Overweight/Obesity
A Clinical Efficacy Study of Asiaticoside for Treating Overweight/Obesity
Source: ClinicalTrials.gov · Last updated 24 Dec 2025
Brief summary (registry, in English)
Centella asiatica is a traditional herbal medicine widely used in China and Southeast Asia for treating various conditions. Preclinical studies have shown that madecassic acid glycosides, including asiaticoside and madecassoside, can significantly reduce body weight gain, adipose tissue mass, and serum triglyceride levels in high-fat diet-induced obese mice. These compounds also improve hepatic steatosis and insulin resistance. This exploratory, interventional study aims to evaluate the clinical efficacy of orally administered asiaticoside tablets in adults with overweight or obesity.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 17 Nov 2025
- Start date
- Dec 2025
- Primary completion date
- Nov 2026
- Lead sponsor
- Shanghai Zhongshan Hospital
- Diseases
- Obesity
- NCT number
- NCT07241533
What you commit to
- Study type: Interventional
- Planned participants: 30
- From Dec 2025 to the primary completion date, Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently receiving other anti-obesity treatments, a previous history of bariatric surgery, or a \>5% reduction in body weight within the past 3 months.
- type 1 or type 2 diabetes mellitus or currently taking hypoglycemic medications.
Other illness
- Active pulmonary tuberculosis, malignant tumors, human immunodeficiency virus (HIV) infection, or other severe infectious or immunocompromising conditions.
- Severe cardiovascular diseases, including angina pectoris, myocardial infarction, or stroke within the past 6 months.
- Severe gastrointestinal disorders, or a history of gastrointestinal surgery within the past year.
- Secondary causes of obesity, including Cushing's syndrome, primary hypothyroidism, hypothalamic obesity, acromegaly; or drug-induced obesity (e.g., antipsychotics, glucocorticoids).
- Unable to complete a 3-month follow-up due to health conditions or relocation.
- Other conditions considered by investigators as unsuitable for participation.
Lab values
- Severe liver injury (AST or ALT \> 3 times the upper limit of normal) or severe renal dysfunction/end-stage renal disease (eGFR \< 30 mL/min/1.73 m²).
Other
- Current smoker or habitual smoker within the past 3 months.
- Pregnancy or planning pregnancy, or breastfeeding.
- Participation in any clinical study within the past 4 weeks.
Who the study is looking for
- Adults aged 18 years or older, male or female.
- Overweight or obesity, defined as a body mass index (BMI) of 24.0-45.0 kg/m².
- Able and willing to provide written informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhongshan Hospital,Fudan University Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.